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Paraneoplastic cerebellar degeneration (PCD) is a common cause of subacute cerebellar
ataxia caused by widespread loss of the Purkinje cells of the cerebellum. PCD diagnosis can
be confirmed by detection of onconeural antibodies that may also indicate the underlying
tumor type [1]. Most onconeural antibodies associated with PCD recognize intracellular
antigens in Purkinje cells [2]. These antigens are supposed to induce, besides the antibody
synthesis, an antigen-specific cytotoxic T-cell attack that probably is responsible of the
Purkinje cell death and limited response to treatment [3,4]. The most common onconeural
antibody in PCD is the Yo antibody that associates with breast and ovarian cancer [4]. In a
previous case report, we identified a new antibody, targeting the intracellular Purkinje cell
protein carbonic anhydrase-related protein VIII (CARPVIII), in a patient with PCD and
melanoma [5]. We provide further evidence for the association of CARP VIII antibodies
with PCD by demonstrating a second patient with these antibodies, who had an ovarian
adenocarcinoma and developed cerebellar ataxia.
A 69-year-old female patient presented with an ovarian papillary serous cystadenocarcinoma
with infiltration of the omentum and peritoneal carcinomatosis that was resected and treated
with chemotherapy for one year. The patient had been in remission for 4 years when she was
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admitted to hospital with the clinical presentation of cerebellar ataxia since 2 weeks, with
vertigo, instability, headache, and vomiting that did not improve upon symptomatic
treatment. Neurological examination revealed vertical nystagmus, dysarthria, intention
tremor of the upper extremities, and gait ataxia. The brain MRI was normal. Abdomen CT
scan detected a paraaortic adenopathy that was confirmed in a biopsy as recurrency of the
ovarian adenocarcinoma. Lumbar puncture showed pleocytosis (290 cells/µl, 94%
lymphocytes) and elevated protein concentration (67mg/dl), with normal glucose levels,
oligoclonal bands were not tested. The serum was investigated for onconeural and surface
receptor antibodies by tissue-based assays and immunoblot [6]. The tissue-based screening
revealed an anti-Purkinje cell antibody of the IgG1 subclass that stained the soma, dendrites,
and axons of Purkinje cells as well as synaptic terminals in the deep cerebellar nuclei (Fig.
1A, B). Currently, three different anti-Purkinje cell antibodies are associated with this
staining pattern and PCD: anti-PKCgamma, described in two patients with adenocarcinomas
[7], anti-ARHGAP26, reported in four patients, including one with ovarian cancer [8,9,10],
and anti-CARP VIII [5]. To further characterize our antibody, we performed an immunoblot
with electrophoretically separated extracts of rat cerebellum. As controls we used serum of
the first published CARP VIII patient [5] and a serum of a healthy individual. The patient’s
antibody detected a protein band with a molecular mass of approximately 29 kDa and was
identical to the band detected by the serum with CARP VIII antibodies (data not shown).
Moreover, we stained filters with purified phage plaques resulting in the specific expression
of CARP VIII, and control phage plaques (which do not result in expression of CARP VIII)
with the patient’s serum, a commercial CARP VIII antibody (Millipore, Billerica, MA,
USA), and serum from a healthy individual (Fig. 1C). The patient’s antibody and the
commercial anti-CARP VIII antibody stained phage plaques expressing CARP VIII,
whereas control plaques remained negative. In addition, we performed a competitive
inhibition of immunohistochemistry, where we first incubated the rat brain section either
with the patient’s serum (Fig. 1D) or a control serum (Fig. 1E) and subsequently with
biotinylated anti-CARP VIII IgG, obtained from the first published case [5]. The
biotinylated anti-CARP VIII antibody immunoreacted with the brain section preincubated
with the negative control, but not with the section pre-incubated with the patient’s serum,
indicating that the antibodies of this patient competed for the same epitopes recognized by
the IgG of the patient with CARP VIII antibodies. Other antibodies such as GAD65 and
classical onconeural antibodies Hu, Yo, Ri, Ma1/2, amphiphysin, SOX1, and CV2/CRMP5
screened by a commercial immunoblot (Ravo Diagnostika, GmbH, Freiburg, Germany)
were negative. Moreover, no surface receptor antibodies (LGI1, CASPR2, NMDAR,
AMPAR, GABA(B)R, DPPX, mGluR1, mGluR5, GlyR) were detectable.
Immunohistochemical analysis of the biopsy material with a commercial anti-CARP VIII
antibody demonstrated robust expression of CARP VIII in the tumor cells (Fig. 1F, G).
Despite of treatment with chemotherapy and intravenous immunoglobulin the cerebellar
syndrome worsened over the following 6 months and the patient became wheelchair
restricted and developed a worsening of dysarthria. Brain MRI showed a progressive
cerebellar atrophy compared to the previous image. The tumor remained in remission until
last follow-up of 9 months.
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We report the second patient with CARP VIII antibodies who also developed PCD.
However, unlike the previously reported patient the underlying tumor was an ovarian
carcinoma that expressed CARP VIII. CARP VIII is related to the family of carbonic
hydrases (CA), a group of enzymes that catalyze CO2 hydration. CARP VIII differs from
this group in lacking the classical CA activity due to the absence of zinc-binding histidine
residues [11]. Human CARP VIII is preferentially expressed in the brain, mainly in Purkinje
cells [11,12]. Beyond Purkinje cells, little or no expression of CARP VIII has been
described in adult human tissue. However, in cancer cells, the protein becomes strongly
upregulated and has been described in different tumor types, including colorectal and non-
small-cell lung carcinoma, where it was associated with higher proliferation and invasive
properties, suggesting a role in tumor growth [12,13]. By immunohistochemistry, CARP
VIII immunoreactivity has been detected in 15% of a series of melanomas and 3% of
ovarian cancers (www.proteinatlas.org). The upregulation of the otherwise neuron-restricted
CARP VIII in tumor cells likely contributes in breaking immune tolerance triggering the
development of CARP VIII antibodies and the expression in different forms of cancer
explains its association with more than one tumor type.
The cerebellar ataxia of our patient occurred at the time of tumor recurrence. Although PCD
usually antedates the tumor diagnosis, it is not unusual that the clinical symptoms arise with
the recurrence of the tumor, which might be explained by a dedifferentiation of tumor cells
and/or change of antigen-presentation [4]. Unfortunately, in our case no tissue of the first
tumor biopsy is available to test whether CARP VIII initially was negative but turned
positive during tumor progression. The role of CARP VIII antibodies in disease evolution is
unclear. CARP VIII is an intracellular protein, thus, the cerebellar degeneration is most
likely T cell mediated and the patient’s antibodies, although of the IgG1 subclass and thus
capable of activating complement, are not directly pathogenic. This is supported by the poor
response to IVIg in both, the first and our CARP VIII patient, and probably neither plasma
exchange nor other B cell targeting strategies might lead to a benefit, although more patients
are needed to determine treatment response and prognosis [14]. However, the diagnosis of
CARP VIII antibodies prompted early tumor diagnosis and removal. Unfortunately the
clinical evolution was not favourable, as it usually happens in patients with anti-Hu and -Yo
antibodies [4].
Our case confirms the association of CARP VIII antibodies with PCD and expands the
spectrum of underlying tumors. Systematic screening for CARP VIII antibodies will detect
more cases of this new paraneoplastic syndrome and can facilitate diagnosis and treatment
of these patients. The possibility of CARPVIII antibodies should be considered in patients
with strong suspicion of PCD and who do not have antibodies against other most common
onconeural antibodies [1].
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Figure 1. Characterization of CARP VIII antibody
(A, B) Patient’s serum strongly labels Purkinje cell cytoplasm (arrows, A), axons
(arrowheads, A), and dendrites (B) in rat cerebellum. (C) Filters with purified phage plaques
expressing CARP VIII specifically reacted with a commercial CARP VIII antibody (1), and
the patient’s serum (2) but not with serum from a healthy individual (3). (D, E) Competitive
inhibition: Immunohistochemistry on rat brain, first incubated with the patient’s serum and
subsequently labeled with a biotinylated CARP VIII antibody, is negative (D, rectangle in
cerebellum enlarged in higher magnification) whereas immunohistochemistry on rat brain
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that was first incubated with a healthy control serum shows strong positive staining with the
biotinylated CARP VIII antibody (E, rectangle in cerebellum enlarged in higher
magnification). (F, G) Tumor biopsy of the ovarian adenocarcinoma shows expression of
CARP VIII in the tumor cells. Magnification: A, F: x200; B, G, and enlarged rectangle in D,
E: x400;
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